Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 29, 2005. The document serves as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It primarily addresses a correction to previously announced dividend dates and discloses changes in directors' interests in company shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is not a financial results report but rather a disclosure of administrative corrections and equity transactions.
Material Changes
The primary material change disclosed is a correction to the dividend schedule for the quarter ended March 31, 2005, which was incorrectly stated in a prior Results Announcement. Additionally, the filing details specific transfers of Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in employee incentive plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The unusual item noted is the correction of the dividend record and payment dates.
Important Facts for Investors
- Dividend Date Correction: The correct dates for the Quarter to 31 March 2005 are: Ex-dividend date (May 11, 2005), Record date (May 13, 2005), and Payment date (July 7, 2005).
- Share Transfers: On April 27, 2005, 1,912 shares were transferred to the SmithKline Beecham Mid Term Incentive Plan.
- Share Transfers: On April 28, 2005, 214,215 shares were transferred to the SmithKline Beecham Employee Share Option Plan 1991.
- Director Interests: Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust, which holds shares for employee benefit plans.